Preventive Health Screening in Adults: What to Order, When, and for Whom
Clinical Practice Update — Cancer, Cardiovascular, Metabolic, and Infectious Disease Screening in Primary Care
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Age- and risk-appropriate preventive screening for cancer, cardiovascular disease, diabetes, hepatitis, HIV, and common metabolic conditions in immunocompetent adults
- Target Audience
- Family physicians, general internists, nurse practitioners, physician assistants, residents
- Setting
- Outpatient primary care, annual wellness visits, preventive health clinics
- Source Evidence
- •USPSTF A & B Recommendations (current through 2025)
- •ACS Cancer Screening Guidelines (2018–2024 updates)
- •AHA/ACC Cardiovascular Risk Assessment Guidelines (2019)
- •ADA Standards of Care in Diabetes (2025)
- •CDC Hepatitis B, Hepatitis C, and HIV Screening Recommendations (2020–2023)
Key Clinical Takeaways
The most important preventive health screening decisions from this Practice Update. Each links to the full discussion below.
- 1Screen overweight or obese adults aged 35–70 for type 2 diabetes — the USPSTF and ADA differ on who else qualifies → Metabolic Screening
- 2Begin colorectal cancer screening at age 45 for average-risk adults — not 50 → Cancer Screening
- 3Lung cancer screening with low-dose CT applies only to heavy smokers aged 50–80 with a 20+ pack-year history → Cancer Screening
- 4Offer one-time hepatitis C screening to every adult aged 18–79, regardless of risk factors → Infectious Disease Screening
- 5Calculate 10-year ASCVD risk before deciding on lipid treatment — the number matters more than the LDL alone → Cardiovascular Screening
- 6Breast cancer screening with mammography should begin at age 40 for average-risk women — USPSTF updated this in 2024 → Cancer Screening
- 7Screen for depression, anxiety, and unhealthy alcohol use at every annual visit — validated tools take under 2 minutes → Behavioural Health Screening
- 8USPSTF and ACS disagree on cervical and breast screening intervals — know where they differ → Where Guidelines Differ
- 9Abdominal aortic aneurysm screening is a one-time ultrasound for men aged 65–75 who have ever smoked → Cardiovascular Screening
- 10Do not order PSA screening without a shared decision-making conversation — the evidence is nuanced → Cancer Screening
Which Cancers Should You Screen For — and When?
Cancer screening decisions depend on age, sex, family history, and individual risk. The biggest changes in recent years have been earlier start ages for colorectal and breast cancer screening. Getting the timing right prevents both missed cancers and unnecessary harm from overscreening.
Perform colorectal cancer screening starting at age 45 for all average-risk adults. Acceptable options include colonoscopy every 10 years, annual FIT, or stool DNA testing every 1–3 years. The strongest evidence supports screening from ages 50 to 75 (USPSTF grade A); screening from 45 to 49 carries a grade B recommendation. For adults aged 76–85, individualise the decision based on overall health and screening history.
Strong Rec High Evidence USPSTF 2021 ACS 2018Perform biennial screening mammography for women aged 40 to 74. The USPSTF updated this recommendation in 2024, lowering the start age from 50 to 40. Evidence is insufficient to assess screening beyond age 74 or the benefit of supplemental screening for dense breasts.
Strong Rec Moderate Evidence USPSTF 2024Perform cervical cancer screening with cytology every 3 years for women aged 21–29. For women aged 30–65, three strategies are acceptable: cytology every 3 years, high-risk HPV testing alone every 5 years, or co-testing (HPV plus cytology) every 5 years. Stop screening after age 65 if prior results have been consistently negative.
Strong Rec High Evidence USPSTF 2018Perform annual low-dose CT for lung cancer screening in adults aged 50–80 who have a 20 pack-year smoking history and currently smoke or quit within the past 15 years. Discontinue once the patient has not smoked for 15 years or develops a condition that substantially limits life expectancy.
Strong Rec Moderate Evidence USPSTF 2021Counsel men aged 55–69 about the potential benefits and harms of PSA-based prostate cancer screening before ordering the test. The decision should be individualised. Do not screen men aged 70 and older routinely.
Conditional Rec Moderate Evidence USPSTF 2018Do not screen for ovarian cancer with CA-125 or transvaginal ultrasound in average-risk women. Available evidence consistently shows no mortality benefit and significant harm from false positives.
Against Moderate Evidence USPSTF 2018How Should You Screen for Cardiovascular Risk?
Cardiovascular disease remains the leading killer of adults in most countries. Screening is not about ordering a single test — it is about calculating risk, identifying modifiable factors, and deciding when treatment changes the trajectory.
Perform blood pressure screening at every clinical encounter for all adults aged 18 and older. Confirm elevated readings with ambulatory or home blood pressure monitoring before diagnosing hypertension.
Strong Rec High Evidence USPSTF 2021Perform lipid panel screening for adults aged 40–75 as part of cardiovascular risk assessment. Use the Pooled Cohort Equations to calculate 10-year ASCVD risk. For adults aged 20–39, check a lipid panel at least once to establish a baseline if cardiovascular risk factors are present.
Strong Rec High Evidence USPSTF 2022 AHA/ACC 2019Consider coronary artery calcium scoring when the statin decision remains uncertain in adults aged 40–75 with a borderline 10-year ASCVD risk of 5–20%. A score of zero may allow deferral of statin therapy.
Moderate Rec Moderate Evidence AHA/ACC 2019Perform one-time abdominal aortic aneurysm screening by ultrasound for men aged 65–75 who have ever smoked. For men in this age group who have never smoked, screening may be considered selectively.
Strong Rec Moderate Evidence USPSTF 2019Prescribe low-dose aspirin for primary cardiovascular prevention only in selected adults aged 40–59 with a 10-year ASCVD risk of 10% or more who are not at increased bleeding risk. Do not initiate aspirin for primary prevention in adults aged 60 and older.
Conditional Rec Moderate Evidence USPSTF 2022When Should You Screen for Diabetes and Metabolic Conditions?
The USPSTF and ADA take different approaches to diabetes screening eligibility. Understanding the distinction matters for deciding whom to test and how to document the rationale.
Perform type 2 diabetes and prediabetes screening with fasting glucose, HbA1c, or oral glucose tolerance test for adults aged 35–70 who have overweight or obesity (BMI 25 or higher). The USPSTF recommends clinicians consider screening earlier in racial and ethnic groups with disproportionately high diabetes prevalence at lower BMI thresholds.
Strong Rec Moderate Evidence USPSTF 2021Consider diabetes screening for all adults aged 45 and older regardless of BMI, and for any adult with one or more additional risk factors (e.g., family history, history of gestational diabetes, polycystic ovary syndrome). This broader approach reflects the ADA criteria, which cast a wider net than the USPSTF.
Moderate Rec Moderate Evidence ADA 2025Refer patients identified with prediabetes to an evidence-based lifestyle intervention programme. Metformin may be considered for high-risk prediabetic patients who do not respond to lifestyle changes.
Strong Rec High Evidence USPSTF 2021 ADA 2025Perform osteoporosis screening with DEXA for all women aged 65 and older. For postmenopausal women younger than 65, screen those whose fracture risk, assessed by a tool such as FRAX, equals or exceeds that of a 65-year-old white woman.
Strong Rec Moderate Evidence USPSTF 2018Which Infections Should Be Detected Early?
Perform one-time hepatitis C virus screening for all adults aged 18–79. Risk-factor-based screening alone misses a substantial number of infections. Curative direct-acting antiviral therapy makes early detection highly impactful.
Strong Rec High Evidence USPSTF 2020Perform HIV screening at least once for all adults and adolescents aged 15–65. Screen more frequently in those at higher risk, including men who have sex with men, persons who inject drugs, and those with a new STI diagnosis.
Strong Rec High Evidence USPSTF 2019Perform one-time universal hepatitis B screening (HBsAg, anti-HBs, total anti-HBc) for all adults aged 18 and older, per CDC 2023 recommendations. Note that the USPSTF 2020 recommendation is more conservative, endorsing screening only in adolescents and adults at increased risk for infection. The CDC’s universal approach simplifies implementation and aligns with elimination goals.
Strong Rec Moderate Evidence CDC 2023 USPSTF 2020 (risk-based)Perform latent tuberculosis screening with interferon-gamma release assay or tuberculin skin test in adults at increased risk, including those born in or who have lived in high-prevalence countries, people experiencing homelessness, and healthcare workers.
Strong Rec Moderate Evidence USPSTF 2016Are You Screening for Mental Health and Substance Use?
Perform depression screening with a validated tool (PHQ-2, PHQ-9) for all adults, including older adults and pregnant and postpartum persons. Ensure systems are in place for follow-up diagnosis, treatment, and monitoring.
Strong Rec Moderate Evidence USPSTF 2023Perform anxiety screening with GAD-7 or equivalent for all adults aged 18–64. Evidence for screening in those aged 65 and older is currently insufficient, but anxiety disorders in older adults are common and undertreated.
Strong Rec Moderate Evidence USPSTF 2023Perform unhealthy alcohol use screening with AUDIT-C or a single-question screen for all adults aged 18 and older. Provide brief behavioural counselling to those who screen positive for risky drinking.
Strong Rec Moderate Evidence USPSTF 2018Perform intimate partner violence screening for all women of reproductive age using a validated tool (e.g., HITS, HARK). Ensure referral pathways to support services are in place before screening.
Strong Rec Moderate Evidence USPSTF 2018Preventive Screening at a Glance: Organised by Age Trigger
This table organises screening by the age at which it first becomes relevant, allowing you to build an age-specific checklist for each patient encounter.
| Age Trigger | Screening | Method | Interval | Easy-to-Miss Pitfall |
|---|---|---|---|---|
| 18+ | Blood pressure | Office measurement, confirm with ABPM or HBPM | Every visit | Single elevated reading does not equal hypertension — always confirm |
| 18+ | Depression, anxiety | PHQ-2/9, GAD-7 (anxiety to age 64) | Annually | Screening without a follow-up pathway in place misses the point |
| 18–79 | Hepatitis C | Anti-HCV antibody, confirm with RNA | Once (repeat if ongoing risk) | Positive antibody requires RNA confirmation — antibody alone does not prove active infection |
| 21+ | Cervical cancer | Cytology (21–29); HPV primary, co-testing, or cytology (30–65) | Every 3–5 years | Screening can stop at 65 only if prior results have been consistently negative |
| 35–70 (if BMI ≥25) | Diabetes / prediabetes (USPSTF) | HbA1c, fasting glucose, or OGTT | Every 3 years | HbA1c can be inaccurate in haemoglobinopathies — use fasting glucose instead |
| 40+ | Breast cancer (women) | Mammography | Every 2 years | Dense breast tissue reduces mammographic sensitivity — supplemental screening evidence is still insufficient |
| 45+ | Colorectal cancer | Colonoscopy, FIT, or stool DNA | Varies by method | FIT requires annual adherence to match colonoscopy’s effectiveness — emphasise this |
| 50–80 (smokers) | Lung cancer | Low-dose CT | Annually | Must actively calculate pack-years — patients often underestimate smoking duration |
| 65+ (women) | Osteoporosis | DEXA scan | Per DEXA result / FRAX | Men on androgen deprivation therapy or long-term steroids also need DEXA — often overlooked |
| 65–75 (male ever-smokers) | AAA | Abdominal ultrasound | Once | “Ever smoked” includes patients who quit decades ago — ask specifically |
- Ages shown are for average-risk adults. Family history, genetic risk, or specific comorbidities may warrant earlier or more frequent screening.
- The “Easy-to-Miss Pitfall” column reflects common documentation and practice errors encountered in primary care.
- Diabetes row shows USPSTF criteria (overweight/obese, 35–70). ADA criteria are broader — see Metabolic Screening section above.
Clinical Decision Pathway
A practical, question-based framework for building a preventive screening plan during an annual wellness visit.
What Should You Avoid Ordering Routinely?
Equally important to knowing what to screen for is knowing what not to order. Low-value screening increases costs, generates false positives, and causes patient anxiety without improving outcomes.
Do not perform routine urinalysis, CBC, or comprehensive metabolic panel as part of preventive health screening in asymptomatic adults without specific clinical indications.
Against Moderate Evidence Choosing WiselyDo not order routine ECG or exercise stress testing for cardiovascular screening in asymptomatic adults at low risk. False positives outnumber true positives in this population and lead to unnecessary invasive testing.
Against Moderate Evidence USPSTF 2018Do not screen for vitamin D deficiency in asymptomatic adults without risk factors. Current evidence is insufficient to determine that population-level screening improves health outcomes.
Against Low Evidence USPSTF 2014Evidence in Context
Where the major guidelines agree, where they differ, and what remains uncertain.
Where USPSTF and ACS Agree
Both organisations agree that colorectal cancer screening should start at age 45, that multiple modalities are acceptable, and that screening should continue through at least age 75. They also align on the critical importance of lung cancer screening with low-dose CT in high-risk smokers, and both support screening cessation after age 65 for cervical cancer if prior results have been normal.
Where USPSTF and ACS Differ
Breast cancer screening interval and age: The USPSTF recommends biennial mammography starting at 40 (updated 2024). The ACS recommends annual mammography from 45 to 54, then biennial from 55 onward, with the option to begin annual screening at 40. The practical difference: the ACS favours annual screening for a longer period.
Cervical cancer screening start age: The USPSTF 2018 recommendation starts cervical screening at age 21 with cytology. The ACS 2020 guideline recommends starting HPV primary testing at age 25, effectively dropping cytology-only screening and starting slightly later. A USPSTF draft update (December 2024) now lists HPV primary testing as the preferred strategy for ages 30–65, narrowing this gap.
Prostate cancer screening: The USPSTF recommends shared decision-making for men aged 55–69 (C recommendation). The ACS recommends an informed decision-making conversation starting at age 50 (or 40–45 for higher-risk men). The philosophy is similar — avoid reflexive screening — but the entry age differs.
Aspirin for Primary Prevention: How the Evidence Shifted
Three major trials published in 2018 — ASPREE (healthy elderly), ARRIVE (moderate-risk adults), and ASCEND (diabetic patients) — collectively demonstrated that for most adults the haemorrhagic risk of daily aspirin offsets the cardiovascular benefit. The USPSTF responded by narrowing the recommendation: aspirin may have a small net benefit for adults aged 40–59 with 10-year ASCVD risk of 10% or more (C recommendation), and the Task Force explicitly recommends against initiation in adults aged 60 and older (D recommendation). This was a significant reversal from prior practice.
Universal Hepatitis Screening: Why the Paradigm Changed
Risk-factor-based HCV screening was shown to miss a large proportion of infections. The availability of curative direct-acting antivirals transformed the cost-effectiveness calculation, and the USPSTF moved to universal screening for ages 18–79 in 2020. For hepatitis B, the USPSTF 2020 recommendation remains risk-based, but the CDC in 2023 adopted universal one-time screening for all adults aged 18 and older, citing the difficulty of implementing risk-based screening and the availability of effective treatment. Clinicians should be aware that USPSTF and CDC diverge on HBV screening scope.
What We Still Don’t Know
References
- 1.US Preventive Services Task Force. A and B Recommendations. uspreventiveservicestaskforce.org
- 2.Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250–281. doi:10.3322/caac.21457
- 3.Arnett DK, Blumenthal RS, Fonarow GC, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596–e646. doi:10.1161/CIR.0000000000000678
- 4.American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1). diabetesjournals.org
- 5.Schillie S, Wester C, Osborne M, et al. CDC Recommendations for Hepatitis C Screening Among Adults — United States, 2020. MMWR Recomm Rep. 2020;69(2):1–17. doi:10.15585/mmwr.rr6902a1
- 6.McNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018;379(16):1509–1518. doi:10.1056/NEJMoa1805819
- 7.Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023. MMWR Recomm Rep. 2023;72(1):1–25. doi:10.15585/mmwr.rr7201a1
- 8.Nicholson WK, Silverstein M, Wong JB, et al. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;331(22):1918–1930. doi:10.1001/jama.2024.5534
How to Read the Evidence Tags
Every recommendation in this article carries two tags indicating how strong the recommendation is and how robust the supporting evidence is. These are Medaptly’s own simplified interpretations for educational clarity.
Recommendation Strength
| Tag | What It Means | In Practice |
|---|---|---|
| Strong Rec | High-quality evidence broadly supports this action. The benefits clearly outweigh the risks for most patients. | This should be standard practice. |
| Moderate Rec | The weight of evidence favours this action, though some uncertainty remains. | Most patients should receive this, but clinical context may lead to a different decision. |
| Conditional Rec | The benefit is less certain. The right choice depends on the individual patient. | Discuss with the patient. Use shared decision-making. |
| Against | Evidence shows no benefit, or the risks outweigh potential benefits. | Avoid this intervention. |
Evidence Quality
| Tag | What It Means | How Confident Can You Be? |
|---|---|---|
| High Evidence | Based on multiple well-designed RCTs or high-quality meta-analyses. | Very confident. Unlikely to change substantially. |
| Moderate Evidence | Based on a single RCT, large observational studies, or meta-analyses with some limitations. | Reasonably confident. Direction likely correct. |
| Low Evidence | Based on expert consensus, small studies, or extrapolated evidence. | Less certain. May change as better evidence emerges. |
These are Medaptly’s simplified interpretations for educational clarity. For the full classification systems used by each source guideline, consult the original documents listed in References.